Development of UV Spectrophotometric Methods for Simultaneous Estimation of Atorvastatin and Telmisartan in Combined Dosage Form Using Simultaneous Equation Method.
L.T. Thote*, A.R. Umarkar and D.R. Chaple,
J. L. Chaturvedi College of Pharmacy, Electronic Zone Building MIDC, Hingna Road, Nagpur, Maharashtra, India Pin 400016
*Corresponding Author E-mail: ltthote@gmail.com
ABSTRACT:
A new, simple, rapid and novel spectrophotometric method has been developed for simultaneous estimation of Atorvastatin and Telmisartan For this, simultaneous equation method is used. The method involved measurement of absorbance at two wavelengths, 246.20 nm and 290 nm, _ max of Atorvastatin and Telmisartan respectively. Beer’s law obeyed in concentration range of 5-30 μg/ mL and 5-30 μg/ mL for Atorvastatin and Telmisartan respectively. The proposed method is recommended for routine analysis since it is rapid, simple, accurate and also sensitive and specific by no heating and no
organic solvent extraction. This paper describes the development and validation of UV spectroscopic method for Simultaneous estimation of Atorvastatin and Telmisartan in combined solid dosage form.
KEYWORDS: Atorvastatin, Telmisartan, Simultaneous Equation Method
INTRODUCTION:
Atrovastatin (fig.1a) chemically it is 2-(4-flurorophenyl) β, δ-dihydroxy-5-isopropyl-3-phenyl-4-(phenylamino) carbonyl-1H-Pyrrole-1-heptanoic acid trihydrate calcium salt1. It is a synthetic lipid lowering agent and an inhibitor of 3-hydroxy-3-methylglutaryl-coenyme A (HMG-CoA) reductase2. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting stage in cholesterol biosynthesis.
Telmisartan (fig.1b) chemically it is 4’-[[4-methyl-6-(1-methyl-1H-benzodiazol-2-yl)-2-propyl-1H-benzodiazol-1-yl] methyl biphenyl-2-carboxylic acid3. It is acts as a selective modulator of Peroxisome proliferator-activated receptor gamma (PPAR-γ), a central regulator of insulin and glucose metabolism4.
(a)
(b)
Fig 1: Chemical structure of Atorvastatin (a); Telmisartan (b)
Literature survey reveals that there are many methods for determination of either ATR or TEL and in combination with other drug in combination dosage forms. None of the reported analytical method describes a simultaneous determination of ATR and TEL in tablet dosage form by UV and HPLC method. Hence it was proposed to attempt the development of simple, accurate, rapid and economic method for simultaneous determination of ATR and TEL in pharmaceutical formulation.
MATERIALS AND METHODS:
Standard Atorvastatin and Telmisartan were provided by Lupin Laboratories, Mumbai. All other chemicals were of analytical grade. Scanning of drugs were done on double beam UV –Spectrophotometer model Shimadzu 1601 with 10 mm matched quartz cells.
Preparation of Standard Drug Solution:
Standard stock solution A: An accurately weighed quantity of ATR (50.0 mg) was dissolved in methanol (25.0 mL) in volumetric flask (50 mL). The volume was made up to mark with methanol. Appropriate dilution were made from this resulting stock solution with methanol so as to get a concentration of 100 µg/mL
Standard stock solution B: An accurately weighed quantity TEL (50.0 mg) was dissolved in methanol (25mL) in volumetric flask (50mL). The volume was made up to mark with methanol. Appropriate dilution were made from this resulting stock solution with methanol so as to get a concentration of 100 µg/mL
Mixed standard stock solution C: An aliquots portion of ATR stock solution and TEL stock solution in the ratio of 1: 2 were mixed volumetric flask (50mL) and volume was adjusted up to mark with methanol.
Procedure for Determine the Sample Wavelength for simultaneous Analysis:
An aliquots portion of standard stock solution of ATR and TEL were appropriately diluted with methanol to get the concentration 10.0 µg/mL and 20.0 µg/mL respectively. The solutions were scanned in range 400 nm to 200 nm against solvent blank. The ATR shows maximum absorbance at 246.20 nm and TEL shows maximum absorbance at 290 nm. The UV absorbance overlain spectrum of drugs are depicted in Fig.2.
Fig 2. Overlain spectra of ATR and TEL
Study of Beer-Lambert’s Law:
The standard solution of ATR and TEL were diluted with methanol to get series of six standard solution having concentration 5, 10, 15, 20, 25 and30 µg/mL respectively. Similarly, mixed standard solution was diluted solution diluted appropriately to get series of concentration ranging from 1 – 10 µg/mL of ATR. The calibrations curves for (A) ATR (B) TEL and (C) Laboratory mixture are depicted in Fig.3. Regression and Optical characteristics of ATOR and CLOP are shown in table no 01. And Results of analysis of laboratory sample are given in table no 2.
Fig 3. Calibrations curves for (A) ATR (B) TEL and (C) Laboratory mixture.
Table 1: Regression and Optical characteristics of ATOR and CLOP
|
Parameters |
Value for ATR |
Value for TEL |
|
Beer’s law limit (µg mL) |
5-30 |
5-30 |
|
Correlation coefficient(r) |
0.9994 |
0.9996 |
|
Regression equation |
||
|
Slop |
0.0232 |
0.0594 |
|
Intercept |
0.0035 |
0.115 |
Table 2: results of analysis of laboratory sample
|
Analyte |
% Concentration estimated* (Mean ± SD) |
Coefficient of Variance |
|
ATOR |
100.35 ±4.39 |
0.0019 |
|
TEL |
100.37 ±0.42 |
0.0018 |
*Average of five determination; R.S.D., Relative standard Deviation
Twenty tablets were weighed and finely powdered. An accurately weighed quantity of the powder equivalent to 10.0 mg of ATR was taken in volumetric flask (50 mL) and dissolved in about 10.0 ml methanol and sonicated for 15 min. it was further diluted up to mark with methanol The resulting solution was filtered and aliquot portion of the filtrate was further diluted to get final concentration of about 2 µg/mL of ATR. The absorbance of solution was measured at two selected wavelengths against blank. The results of assay of tablet are given in Table 3. and results recovery study are given in table no 4.
Table 3: Results of analysis of tablet sample
|
Analyte |
Label claim (mg/tab) |
% Label claim estimated*(Mean± S.D.) |
|
ATOR |
10 |
100.85 |
|
TEL |
20 |
101.37 |
Table 4: Recovery study
|
Drug in standard mixture solution (µg ml) |
% Recovery ± S.D.* |
Coefficient of Variance |
|||
|
ATOR |
TEL |
ATOR |
TEL |
ATOR |
TEL |
|
1 |
2 |
99.24± 1.07 |
99.92±0.31 |
0.0114 |
0.0005 |
|
2 |
4 |
99.70±0.86 |
97.15±167 |
0.0073 |
0.280 |
|
3 |
6 |
100.90±0.25 |
100.91±0.18 |
0.006 |
0.003 |
S.D.* Standard deviation the results of mean of three reading (n=3)
CONCLUSION:
The most striking feature of this method is its simplicity and rapidity, non-requiring- consuming sample preparation such as extraction of solvents, heating, degassing which are needed for HPLC procedure. It is analysis in quality control analysis. The described method gives accurate and precise results for Atorvastatin and Telmisartan in combined solid dosage form.
RESULTS AND DISSUSSION:
The proposed method for simultaneous estimation of ATOR and TEL in combined sample solution was found to be simple, accurate and reproducible. Beer’s law was obeyed in concentration range of 5-30 µg/ml and 5-30 µg/ml for ATR and TEL. Coefficient of variation was found to be 0.9994 and 0.9995 for ATOR and TEL, respectively. The percentage recoveries were found to be in the range of 101.41±1.095 and 100.54±1.003 for ATOR and TEL respectively. Once the equations are determined, analysis requires only the measuring of the absorbance of the sample solution at two wavelengths selected, followed by few simple calculation.
ACKNOWLEDGEMENT:
The authors are grateful to Lupin laboratories for providing standard Atorvastatin and Telmisartan. We are also like to thanks head of the J. L. Chaturvedi College of Pharmacy, Electronic Zone Building MIDC Hingna Road, Nagpur for providing instrumental facility regarding our project work.
REFERENCE:
1. Myrdele, J. O., Catherine, M. K. and Maryann, R. D., In; The Merck index. An Encyclopedia of Chemicals, Drugs and Biologicals. Whitehouse station, N U, USE. 14 th Edn., 2006, 143.
2. Gholamreza, B., Mohammadi, B., Kinani, A., J Chromatogr. B, 2005, 41.
3. Torrealdy, N., Gonza, L., Alonso, R. M., J. Pharm. Biomed. Anal., 32, 2003, 847
4. Marria, R. S., Yaritza, C., Alonso, Sabrina, M. R., J. Pharm. Biomed. Anal., 50, 2009, 194.
Received on 30.08.2011 Modified on 04.09.2011
Accepted on 25.09.2011 © AJRC All right reserved
Asian J. Research Chem. 4(11): Nov., 2011; Page 1777-1779